Here's Why Novo Nordisk Stock Popped Today
Key Points
The company's highly promising drug, amycretin, reported impressive results in a trial for Type 2 diabetes.
The news follows on for a disappointing, but hardly unexpected, result in a Phase 3 trial for semaglutide in Alzheimer's.
- 10 stocks we like better than Novo Nordisk ›
Another day and another release of results from a clinical trial from Novo Nordisk (NYSE: NVO). However, this time it's positive news. Here's the lowdown.
Novo Nordisk trial results
The pharmaceutical company is best known for semaglutide, which is approved to treat Type 2 diabetes (Wegovy) and, most famously, obesity (Wegovy). It's part of an exciting class of drugs, GLP-1 receptor agonists, which includes Eli Lilly's tirzepatide (approved as Mounjaro for Type 2 Diabetes and Zepbound for obesity).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Yesterday's "bad" news from Novo Nordisk came from its Phase 3 trials of oral semaglutide in the early stage of Alzheimer's disease. The trials did not establish the superior efficacy of oral semaglutide over placebo in the trial. I've used inverted commas because the Alzheimer's trial was always a low probability event – a Novo Nordisk executive had reportedly described it as a lottery, and few people expect to win lotteries.
On a more positive note, Novo Nordisk reported positive results from a Phase 2 trial of its next highly promising GLP-1 receptor agonist, amycretin, in Type 2 diabetes. The trial combined a once-weekly subcutaneous (under the skin) dosage with a once-daily oral form dosage, and resulted in 14.5% weight loss at 36 weeks.
Image source: Getty Images.
For reference, Novo Nordisk is already advancing amycretin into Phase 3 trials for obesity, in both subcutaneous and oral forms. The company is also anticipating Food and Drug Administration (FDA) approval of oral Wegovy by year's end.
It strikes me that the positive news from the amycretin Phase 2 today is more of an event than the negative news on the semaglutide Phase 3 in Alzheimer's, but the market disagrees, as the stock is still down over the last two days, despite today's recovery.
Should you invest $1,000 in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $576,882!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,119,006!*
Now, it’s worth noting Stock Advisor’s total average return is 1,002% — a market-crushing outperformance compared to 190% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of November 24, 2025
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
